Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.47 |
| ▸ | CTSS | P25774 | 6/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16488750 | 1.00 | CTSK (0.47) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL14673227 | 1.00 | CTSK (0.47) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL16488743 | 1.00 | CTSK (0.47) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL7105585 | 0.83 | CTSK (0.43) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL7105576 | 0.83 | CTSK (0.43) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL2418915 | 0.83 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL6476152 | 0.83 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL14453090 | 0.83 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL14038647 | 0.83 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 | |
| SCHEMBL1536324 | 0.83 | CTSK (0.49) | CTSKCTSSCA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190135862-A1 | NDMA RECEPTOR MODULATORS AND USES THEREOF | INNOVIVA TRC HOLDINGS LLC | 2019-05-09 | — | — | US | disclosed |
| US-20190135862-A1 | NDMA RECEPTOR MODULATORS AND USES THEREOF | INNOVIVA TRC HOLDINGS LLC | 2019-05-09 | — | — | US | disclosed |
| US-20180325893-A1 | SUBACUTE ADMINISTRATION OF NMDA MODULATORS ALONE OR IN COMBINATION | UNIV NORTHWESTERN (US) | 2018-11-15 | — | — | US | disclosed |
| EP-2771021-B1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NORTH WESTERN UNIV (US) | 2018-08-29 | — | — | EP | disclosed |
| US-20180237474-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | INNOVIVA TRC HOLDINGS LLC | 2018-08-23 | — | — | US | disclosed |
| US-20160368947-A1 | NMDA Receptor Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2016-12-22 | — | — | US | disclosed |
| US-20160368947-A1 | NMDA Receptor Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2016-12-22 | — | — | US | disclosed |
| US-20160368947-A1 | NMDA Receptor Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2016-12-22 | — | — | US | disclosed |
| US-20150315237-A1 | NMDA Receptor Modulators and Uses Thereof | NORTHWESTERN UNIVERSITY | 2015-11-05 | — | — | US | disclosed |
| US-20150051262-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NORTHWESTERN UNIVERSITY (US) | 2015-02-19 | — | — | US | disclosed |
| US-20150051262-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NORTHWESTERN UNIVERSITY (US) | 2015-02-19 | — | — | US | disclosed |
| US-20150051262-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NORTHWESTERN UNIVERSITY (US) | 2015-02-19 | — | — | US | disclosed |
| EP-2771021-A2 | NMDA RECEPTOR MODULATORS AND USES THEREOF | North Western University (US) | 2014-09-03 | — | — | EP | disclosed |
| US-8673843-B2 | NMDA receptors modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673843-B2 | NMDA receptors modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2014-03-18 | — | — | US | disclosed |
| US-8673843-B2 | NMDA receptors modulators and uses thereof | NORTHWESTERN UNIVERSITY (US) | 2014-03-18 | — | — | US | disclosed |
| WO-2013063120-A2 | NMDA RECEPTOR MODULATORS AND USES THEREOF | NORTHWESTERN UNIVERSITY (US) | 2013-05-02 | — | — | WO | disclosed |
| US-20130035292-A1 | NMDA Receptors Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2013-02-07 | — | — | US | disclosed |
| US-20130035292-A1 | NMDA Receptors Modulators and Uses Thereof | INNOVIVA TRC HOLDINGS LLC | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190135862-A1 | NDMA RECEPTOR MODULATORS AND USES THEREOF | OPRL1, GRIN2A, GRM1 | CTSK 3678/4885CTSS 4587/4885CA1 2600/4885 |
| US-20150051262-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | CTSK 3534/4885CTSS 4481/4885CA1 1310/4885 |
| US-20150315237-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | CTSK 3534/4885CTSS 4481/4885CA1 1310/4885 |
| US-20160368947-A1 | NMDA Receptor Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | CTSK 3534/4885CTSS 4481/4885CA1 1310/4885 |
| US-20180325893-A1 | SUBACUTE ADMINISTRATION OF NMDA MODULATORS ALONE OR IN COMBINATION | GRIN2A, GRIN2D, GRIN1 | CTSK 2276/4885CTSS 2189/4885CA1 1700/4885 |
| US-20180237474-A1 | NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN3A | CTSK 3534/4885CTSS 4481/4885CA1 1310/4885 |
| US-20130035292-A1 | NMDA Receptors Modulators and Uses Thereof | GRIN1, GRIN2A, GRIN3A | CTSK 3602/4885CTSS 4453/4885CA1 1277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.